PARIS--(BUSINESS WIRE)--Nanobiotix, a company developing cancer novel nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS1, to start the first clinical trial2.